Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT ID: NCT06362590

Last Updated: 2025-06-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ladiratuzumab vedotin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seagen Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Seagen Trial Information Support

Role: CONTACT

866-333-7436

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LV-SPIND-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432 RECRUITING PHASE1/PHASE2
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121 ACTIVE_NOT_RECRUITING PHASE1